The pharmaceutical and bioanalytical contract solutions provider is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, Illinois
The expansion will increase the site’s current footprint from 38,500 sqft to nearly 58,000 sqft and is due to be completed by September 2017.
The expansion will allow the facility to increase capacity for the wide range of services it offers, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will also be employed to meet the demands of the laboratory.
James Nokes, VP of US Agriculture, Food and Life at SGS, said: “This investment allows us to be flexible in our approach to meeting both existing and future customer demands. Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs.
"At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity and our staff to maintain our professionalism and efficiency.”
The expansion at SGS’s Lincolnshire site follows a series of recent investments at the company’s global laboratory network. Increases in extractables and leachables capabilities have taken place at Fairfield, NJ and Shanghai, China; while French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis respectively.
In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management and services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance, and regulatory consultancy.